| |
|
|
|
|
|
 |
| |
|
ºñºñ·Ð¿¬Áúݼ¿ VIVIRON SOFT CAPSULE[Dl-magnesium aspartate , Haematoporphyrin , Magnesium Oxide , Magnesium Sulfate , Orotic acid , Procaine HC
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¿¯Àº°¥»öÀÇ À¯µ¿¼º ³»¿ë¹°ÀÌ µé¾î ÀÖ´Â À广ÇüÀÇ Àû°¥»ö ¿¬Áúݼ¿Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Á¤½ÅÀû, À°Ã¼Àû ÇÇ·Î, º´ÈÄȸº¹, °æ»öÁõ, µ¿¸Æ°æÈÁõ, ¹«·Â°¨
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Magnesium Sulfate][Procaine]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ÀÏ 1-2ݼ¿ º¹¿ëÇÑ´Ù.
|
| ±Ý±â |
- ÇÁ·ÎÄ«ÀÎ, ¾È½ÄÇâ»ê, ¼³Æù¾Æ¹Ìµå¿¡ ´ëÇÏ¿© ¾Ë·¹¸£±â¼º ȯÀÚ
- ¼³Æù¾Æ¹Ìµå¿¡ °üÇÑ °áÇÕȯÀÚ
- Äݸ°¿¡½ºÆ®¶óÁ¦ ¾ïÁ¦¿¡ °üÇÑ °áÇÕȯÀÚ
- ÀÇÄݸ°¿¡½ºÆ®¶óÁ¦ °áÇÕȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- À§ÀåÀå¾Ö(¸Þ½º²¨¿ò, À§Åë, ¼³»ç, ±¸Åä)
- Çö±â
- ȯ°¢»óÅÂ
- Æó°æ±âÈÄ ¼º±âÀÇ ÃâÇ÷
- ¾Ë·¹¸£±â¼º ¹ÝÀÀ
|
| »óÈ£ÀÛ¿ë |
- ¼³Æù¾Æ¹Ìµå È¿·Â°¨¼Ò
- ÇÁ·ÎÄ«ÀνºÇÇ°Ö Áõ°¡(Çϰ¾ïÁ¦)
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| BIT ¾àÈ¿ºÐ·ù |
±âŸ ºñŸ¹Î/¿µ¾çÁ¦·ù (Other Vitamins & Nutritional Supplements)
|
| ATC ÄÚµå |
Various alimentary tract and metabolism products / A16AX
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
329 (±âŸÀÇ ÀÚ¾ç°À庯ÁúÁ¦ )
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(procaine; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Magnesium¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Magnesium¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Not Available
Procaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
|
| Pharmacology |
Procaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine.
|
| Protein Binding |
Procaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Procaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 7.7 minutes
|
| Absorption |
Procaine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Magnesium OxideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °øÀå, ȸÀå¿¡¼ ´Éµ¿, ¼öµ¿ Èí¼ö
- »çÇÏÀÛ¿ë ¹ßÇö : 4-8 ½Ã°£
- ÃѴܹé°áÇÕÀ² : 33%
- ¼Ò½Ç : Èí¼öµÈ ¸¶±×³×½·Àº ½Å¼ÓÇÏ°Ô ½ÅÀå ¹è¼³, Èí¼öµÇÁö ¾ÊÀº ¸¶±×³×½·Àº ´ëº¯ ¹è¼³
Magnesium SulfateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- °æ±¸ : »çÇÏÀÛ¿ë ¹ßÇö½Ã°£ : 1-2 ½Ã°£ À̳»
- ±ÙÀ°ÁÖ»ç :
- ÀÛ¿ë¹ßÇö½Ã°£ : 1½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 3-4 ½Ã°£
- Á¤¸ÆÁÖ»ç :
- ÀÛ¿ë¹ßÇö½Ã°£ : Áï½Ã ¹ßÇö
- ÀÛ¿ëÁö¼Ó½Ã°£ : 30ºÐ
- ¼Ò½Ç : ÁÖ·Î ´ëº¯À¸·Î ¹è¼³µÈ´Ù. Èí¼öµÈ magnesiumÀº ½Å¼ÓÇÏ°Ô ½ÅÀåÀ¸·Î ¹è¼³µÈ´Ù.
Dl-magnesium aspartateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : º¹¿ë·®ÀÇ ¨÷-¨öÀÌ ¼ÒÀå¿¡¼ ¼¼È÷ Èí¼öµÈ´Ù.
- ´Ü¹é°áÇÕ : ¾à 25-30%
- ¼Ò½Ç : Èí¼öµÈ ¾çÀÇ 90% ÀÌ»óÀÌ ½Å¹è¼³µÈ´Ù.
Tocopherol AcetateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ :
- ¼ÒÀåÀ¸·ÎºÎÅÍ Èí¼öµÇ´Â µ¥¿¡´Â ´ãÁóÀÌ ÇÊ¿äÇÏ´Ù.
- Èí¼ö ÀúÇÏ : Èí¼öÀå¾Ö ȯÀÚ, ÀúüÁß ¹Ì¼÷¾Æ, °í¿ë·® Åõ¿©
- À¯ÈÁ¦Á¦º¸´Ù ¼ö¿ë¼º Á¦Á¦°¡ ´õ Àß Èí¼öµÈ´Ù.
- ºÐÆ÷ : ¸ðµç Á¶Á÷¿¡ ºÐÆ÷Çϸç, ƯÈ÷ Áö¹æÁ¶Á÷¿¡ °í³óµµ·Î ºÐÆ÷Çϰí ÀúÀåµÈ´Ù.
- ´ë»ç : °£¿¡¼ glucuronides Æ÷ÇÕ
- ¼Ò½Ç : ÁÖ·Î ´ãÁóÀ» ÅëÇØ (70-80%) ¹è¼³µÈ´Ù.
Procaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : ÁÖ»çÁ¦ : 2-5ºÐ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 0.5-1.5 ½Ã°£ (ȯÀÚ, Â÷´Ü¹æ¹ý, ³óµµ, ¸¶Ãë¹æ¹ý¿¡ ÀÇÁ¸Àû)
- ´ë»ç : Ç÷Àå È¿¼Ò¿¡ ÀÇÇØ p-aminobenzoic acid, diethylaminoethanol·Î ºü¸£°Ô °¡¼öºÐÇØµÊ. ¹è¼³µÇ±â Àü¿¡ 80%´Â Æ÷ÇÕµÊ
- ¹Ý°¨±â : 7.7ºÐ
- ¼Ò½Ç : ´ë»çü ¹× ÀϺΠ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Procaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hydrolysis by plasma esterases to PABA
|
| Toxicity |
Procaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Magnesium¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Formation of non-absorbable complexesCiprofloxacin Formation of non-absorbable complexesClodronate Formation of non-absorbable complexesDemeclocycline Formation of non-absorbable complexesDoxycycline Formation of non-absorbable complexesEnoxacin Formation of non-absorbable complexesEtidronic acid Formation of non-absorbable complexesGatifloxacin Formation of non-absorbable complexesGemifloxacin Formation of non-absorbable complexesGrepafloxacin Formation of non-absorbable complexesIbandronate Formation of non-absorbable complexesLevofloxacin Formation of non-absorbable complexesLomefloxacin Formation of non-absorbable complexesMethacycline Formation of non-absorbable complexesMinocycline Formation of non-absorbable complexesMoxifloxacin Formation of non-absorbable complexesNorfloxacin Formation of non-absorbable complexesOfloxacin Formation of non-absorbable complexesOxytetracycline Formation of non-absorbable complexesPefloxacin Formation of non-absorbable complexesRisedronate Formation of non-absorbable complexesTrovafloxacin Formation of non-absorbable complexesTetracycline Formation of non-absorbable complexesTemafloxacin Formation of non-absorbable complexesAmprenavir The antiacid decreases the absorption of amprenavirChloroquine The antiacid decreases the absorption of chloroquineAtazanavir This gastric pH modifier decreases the levels/effects of atazanavirDelavirdine The antiacid decreases the absorption of delavirdineDihydroquinidine barbiturate The antiacid decreases the absorption of quinidineFosamprenavir The antiacid decreases the absorption of amprenavirIndinavir The antiacid decreases the absorption of indinavirQuinidine The antiacid decreases the absorption of quindineQuinidine barbiturate The antiacid decreases the absorption of quinidinePolystyrene sulfonate Risk of alkalosis in renal impairmentRosuvastatin The antiacid decreases the absorption of rosuvastatin
Procaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aluminium Formation of non-absorbable complexesBismuth Formation of non-absorbable complexesCalcium Formation of non-absorbable complexesDihydroxyaluminium Formation of non-absorbable complexesEstramustine Increases the levels of estramustineMagnesium oxide Formation of non-absorbable complexesMagnesium Formation of non-absorbable complexesSucralfate Formation of non-absorbable complexesIron Formation of non-absorbable complexes
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Procaine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Magnesium¿¡ ´ëÇÑ Description Á¤º¸ Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.
Procaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [PubChem]
|
| Dosage Form |
Magnesium¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol OralCapsule OralLiquid IntramuscularLiquid IntravenousLiquid OralOintment TopicalPellet OralPowder OralSolution IntramuscularSolution IntravenousSolution OralSolution / drops OralSuspension OralSyrup OralTablet Oral
Procaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSolution InfiltrationSolution IntramuscularTablet, extended release Oral
|
| Drug Category |
Magnesium¿¡ ´ëÇÑ Drug_Category Á¤º¸ Not Available
Procaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalLocal Anesthetics
|
| Smiles String Canonical |
Magnesium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Mg++]
Magnesium¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Mg++]
Procaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
|
| Smiles String Isomeric |
Magnesium¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Mg++]
Procaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
|
| InChI Identifier |
Magnesium¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/Mg/q+2
Procaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
|
| Chemical IUPAC Name |
Magnesium¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ magnesium(+2) cation
Procaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 4-aminobenzoate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-05-27
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|